Loading...
•
Sep 30, 2020
Teva Q3 2020 Earnings Report
Revenues decreased by 3% and GAAP diluted loss per share was $3.97.
Key Takeaways
Teva's Q3 2020 results showed resilience amidst the COVID-19 pandemic with revenues of $4.0 billion and non-GAAP diluted EPS of $0.58. The company launched digital inhalers and reduced net debt by more than $10 billion over three years.
Revenues in the third quarter of 2020 were $3,978 million, a decrease of 3% compared to the third quarter of 2019.
GAAP diluted loss per share was $3.97, while non-GAAP diluted EPS was $0.58.
Free cash flow for the quarter was $506 million.
The company launched digital inhalers AirDuo Digihaler and ArmonAir Digihaler in the U.S.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comRevenue by Geographic Location
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Teva revised its full year 2020 business outlook, projecting net revenues of $16.5-16.8 billion, EBITDA of $4.7 - $4.9 billion, EPS of $2.40 - $2.55, and Free cash flow of $1.8 - $2.2 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income